Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD
- MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021
- The designation is intended to accelerate the timeline for approval of innovative medicines for treatment of life-threatening conditions or those which present a significant patient or public health need
- MAPS Public Benefit Corporation will coordinate trial design with Medicines and Healthcare products Regulatory Agency to create a road map for early patient access in the UK
Filament Health Subsidiary Psilo Scientific Announces Inclusion in Health Canada List of Licensed Psilocybin Producers
“Our inclusion in this list will aid us in adding to our growing number of partnerships in the Canadian psychedelic ecosystem,” said Benjamin Lightburn, Chief Executive Officer of Filament Health. “We commend Health Canada on their continuing support of the SAP and of scientific research into psychedelics.”
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
The company announced its financial results and operational highlights. Click here to see the details
.
ATAI Launches Discovery Program for Next-Gen Mental Health Treatments
Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs)
Numinus Identified as a Licensed Psilocybin Supplier by Health Canada
This list is available by request to those seeking access to psilocybin through the Special Access Program (SAP), and clinical researchers. “Through our inclusion, we look forward to collaborating with healthcare providers and other groups to ensure people in need receive efficacious treatments,” said Sharan Sidhu, Science Officer and General Manager, Numinus Bioscience.
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
The Company issued 4,750,000 Common Shares, 7,750,000 Common Share equivalents and Warrants to purchase up to an aggregate of 12,500,000 Common Shares, at a purchase price of CAD$0.40 per Common Share. H.C. Wainwright & Co. acted as the exclusive placement agent for the Private Placement in the United States.